OnKure Therapeutics, Inc. (OKUR) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Boulder, CO, United States. El CEO actual es Nicholas A. Saccomano.
OKUR tiene fecha de IPO 2021-04-08, 46 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $61.67M.
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
